Anzeige
Mehr »
Login
Samstag, 27.11.2021 Börsentäglich über 12.000 News von 683 internationalen Medien
Personalisierte Medizin ist die Zukunft! Milliarden-Gewinne durch psychedelische Therapeutika!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H8QW ISIN: AU000000KZA9 Ticker-Symbol: NV9 
München
26.11.21
08:03 Uhr
0,900 Euro
-0,025
-2,70 %
Branche
Pharma
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
KAZIA THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
KAZIA THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,8500,88026.11.

Aktuelle News zur KAZIA THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKAZIA THERAPEUTICS LIMITED: Notification of cessation of securities - KZA-
16.11.KAZIA THERAPEUTICS LIMITED: Notification regarding unquoted securities - KZA1
KAZIA THERAPEUTICS Aktie jetzt für 0€ handeln
14.11.KAZIA THERAPEUTICS LIMITED: Kazia appoints John Friend as CMO-
11.11.Kazia Therapeutics gets enrollment underway in early-stage EVT801 cancer study-
10.11.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
10.11.KAZIA THERAPEUTICS LIMITED: Kazia AGM - Results of Meeting2
09.11.KAZIA THERAPEUTICS LIMITED: Chairman's Address to Shareholders-
09.11.KAZIA THERAPEUTICS LIMITED: Kazia enrols first patient to PNOC study-
04.11.Kazia Therapeutics Limited: Kazia Enrols First Patient to EVT801 Phase I Clinical Trial82SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment...
► Artikel lesen
04.11.Kazia Therapeutics enrols first patient in EVT801 trial2
03.11.KAZIA THERAPEUTICS LIMITED: Notification of cessation of securities - KZA-
03.11.KAZIA THERAPEUTICS LIMITED: Notification of cessation of securities - KZA-
02.11.KAZIA THERAPEUTICS LIMITED: Kazia enrols first patient to EVT801 Phase I clinical trial1
29.10.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer2
14.10.Edison Investment Research Limited: Kazia Therapeutics (KZIA): Multiple Paxalisib Data Points Expected in Q4334LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly...
► Artikel lesen
13.10.Kazia Therapeutics - Multiple paxalisib data points expected in Q4228Kazia expects to release multiple data points from its paxalisib programme in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients...
► Artikel lesen
13.10.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
11.10.KAZIA THERAPEUTICS LIMITED: Notice of General Meeting/Proxy Form-
07.10.KAZIA THERAPEUTICS LTD - 20-F, Annual and transition report of foreign private issuers1
20.09.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
Seite:  Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1